(BRKR) Bruker - Ratings and Ratios
Spectrometers, Microscopes, NMR, AFM, X-Ray
Dividends
| Dividend Yield | 0.44% |
| Yield on Cost 5y | 0.38% |
| Yield CAGR 5y | 5.74% |
| Payout Consistency | 96.5% |
| Payout Ratio | 11.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 40.2% |
| Value at Risk 5%th | 62.5% |
| Relative Tail Risk | -5.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -40.15 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.401 |
| Beta | 1.126 |
| Beta Downside | 1.077 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.72% |
| Mean DD | 30.41% |
| Median DD | 30.00% |
Description: BRKR Bruker November 05, 2025
Bruker Corporation (NASDAQ: BRKR) designs, manufactures, and sells a broad array of scientific instruments and analytical solutions across the United States, Europe, Asia-Pacific, and other international markets. The firm operates through four primary segments-Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies-covering magnetic-resonance spectroscopy, pre-clinical imaging, mass spectrometry, MALDI-Biotyper microbial identification, portable X-ray fluorescence, atomic-force microscopy, and superconducting-material equipment.
In fiscal 2023 Bruker reported revenue of roughly $2.2 billion, up about 5 % year-over-year, with an operating margin near 13 % and research-and-development spending representing roughly 12 % of sales. The life-sciences tools sector is projected to grow at a 6 % compound annual growth rate through 2028, driven by expanding biotech R&D pipelines, increased government funding for genomics and proteomics, and a shift toward high-throughput, multi-omics platforms-trends that directly benefit Bruker’s BSI and diagnostic product lines.
Given Bruker’s diversified product mix, solid cash generation, and exposure to fast-growing scientific-instrument markets, a deeper quantitative view of its valuation metrics can be valuable; the ValueRay platform provides a data-driven analysis that may help you refine your investment thesis.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-20.9m TTM) > 0 and > 6% of Revenue (6% = 206.3m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -2.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.48% (prev 26.82%; Δ 4.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 94.3m > Net Income -20.9m (YES >=105%, WARN >=100%) |
| Net Debt (1.75b) to EBITDA (288.6m) ratio: 6.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (151.8m) change vs 12m ago -0.13% (target <= -2.0% for YES) |
| Gross Margin 47.36% (prev 48.95%; Δ -1.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.81% (prev 53.02%; Δ 1.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.14 (EBITDA TTM 288.6m / Interest Expense TTM 64.4m) >= 6 (WARN >= 3) |
Altman Z'' 2.98
| (A) 0.17 = (Total Current Assets 2.35b - Total Current Liabilities 1.27b) / Total Assets 6.43b |
| (B) 0.37 = Retained Earnings (Balance) 2.35b / Total Assets 6.43b |
| (C) 0.01 = EBIT TTM 73.5m / Avg Total Assets 6.27b |
| (D) 0.58 = Book Value of Equity 2.27b / Total Liabilities 3.94b |
| Total Rating: 2.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.36
| 1. Piotroski 2.0pt |
| 2. FCF Yield -0.12% |
| 3. FCF Margin -0.31% |
| 4. Debt/Equity 0.84 |
| 5. Debt/Ebitda 6.08 |
| 6. ROIC - WACC (= -6.66)% |
| 7. RoE -1.07% |
| 8. Rev. Trend 83.24% |
| 9. EPS Trend -37.18% |
What is the price of BRKR shares?
Over the past week, the price has changed by -5.94%, over one month by +6.32%, over three months by +46.38% and over the past year by -22.50%.
Is BRKR a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BRKR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.8 | 8.2% |
| Analysts Target Price | 48.8 | 8.2% |
| ValueRay Target Price | 47.3 | 4.8% |
BRKR Fundamental Data Overview December 03, 2025
P/E Forward = 22.0264
P/S = 2.1146
P/B = 3.0496
P/EG = 3.64
Beta = 1.198
Revenue TTM = 3.44b USD
EBIT TTM = 73.5m USD
EBITDA TTM = 288.6m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 24.3m USD (from shortTermDebt, last quarter)
Debt = 2.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.75b USD (from netDebt column, last quarter)
Enterprise Value = 9.03b USD (7.27b + Debt 2.05b - CCE 295.0m)
Interest Coverage Ratio = 1.14 (Ebit TTM 73.5m / Interest Expense TTM 64.4m)
FCF Yield = -0.12% (FCF TTM -10.6m / Enterprise Value 9.03b)
FCF Margin = -0.31% (FCF TTM -10.6m / Revenue TTM 3.44b)
Net Margin = -0.61% (Net Income TTM -20.9m / Revenue TTM 3.44b)
Gross Margin = 47.36% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 44.88% (prev 44.88%)
Tobins Q-Ratio = 1.40 (Enterprise Value 9.03b / Total Assets 6.43b)
Interest Expense / Debt = 0.98% (Interest Expense 20.0m / Debt 2.05b)
Taxrate = 19.42% (-14.1m / -72.6m)
NOPAT = 59.2m (EBIT 73.5m * (1 - 19.42%))
Current Ratio = 1.85 (Total Current Assets 2.35b / Total Current Liabilities 1.27b)
Debt / Equity = 0.84 (Debt 2.05b / totalStockholderEquity, last quarter 2.43b)
Debt / EBITDA = 6.08 (Net Debt 1.75b / EBITDA 288.6m)
Debt / FCF = -165.5 (out of range, set to none) (Net Debt 1.75b / FCF TTM -10.6m)
Total Stockholder Equity = 1.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.32% (Net Income -20.9m / Total Assets 6.43b)
RoE = -1.07% (Net Income TTM -20.9m / Total Stockholder Equity 1.96b)
RoCE = 1.86% (EBIT 73.5m / Capital Employed (Equity 1.96b + L.T.Debt 1.98b))
RoIC = 1.44% (NOPAT 59.2m / Invested Capital 4.12b)
WACC = 8.10% (E(7.27b)/V(9.32b) * Re(10.16%) + D(2.05b)/V(9.32b) * Rd(0.98%) * (1-Tc(0.19)))
Discount Rate = 10.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.97%
Fair Price DCF = unknown (Cash Flow -10.6m)
EPS Correlation: -37.18 | EPS CAGR: -6.97% | SUE: 2.38 | # QB: 1
Revenue Correlation: 83.24 | Revenue CAGR: 6.33% | SUE: 0.69 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.42 | Chg30d=-0.062 | Revisions Net=-4 | Analysts=10
EPS next Year (2026-12-31): EPS=2.15 | Chg30d=-0.109 | Revisions Net=-10 | Growth EPS=+14.5% | Growth Revenue=+1.7%
Additional Sources for BRKR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle